KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation

PLoS One. 2017 Jul 7;12(7):e0180831. doi: 10.1371/journal.pone.0180831. eCollection 2017.

Abstract

Background: Kidney transplantation is a life-saving treatment for patients with end-stage renal disease. However, despite progress in surgical techniques and patient management, immunological rejection continues to have a negative impact on graft function and overall survival. Incompatibility between donors and recipients for human leukocyte antigens (HLA) of the major histocompatibility complex (MHC) generates a series of complex cellular and humoral immune response mechanisms that are largely responsible for rejection and loss of graft function. Within this context, a growing amount of evidence shows that alloreactive natural killer (NK) cells play a critical role in the immune response mechanisms elicited by the allograft. Killer immunoglobulin-like receptors (KIRs) are prominent mediators of NK cell alloreactivity.

Methods and findings: A cohort of 174 first cadaveric kidney allograft recipients and their donors were selected from a total cohort of 657 transplanted patients for retrospective immunogenetic analyses. Patients with HLA Class II mismatches were excluded. HLA Class I allele frequencies were compared among patients with chronic rejection, patients with stable graft function and a group of 2388 healthy controls. Activating and inhibitory KIR gene frequencies, KIR haplotypes, KIR-HLA ligand matches/mismatches and combinations of recipient KIRs and donor HLA Class I ligands were compared among patients with and without chronic rejection and a group of 221 healthy controls. Patients transplanted from donors homozygous for HLA-C1 antigens had a significantly higher risk for chronic rejection than patients transplanted from donors homozygous or heterozygous for HLA-C2 antigens or with epitopes belonging to the HLA-Bw4 ligand group. The Kaplan-Meier curves obtained by dividing the patients into 3 groups according to the presence or absence of one or both of the combinations of recipient KIRs and donor HLA ligands (rKIR2DL1/dHLA-C2 and rKIR3DL1/dHLA-Bw4) showed a significantly higher cumulative incidence of chronic rejection in the group of patients completely lacking these functional units. These patients showed a progressively stronger decline in modification of diet in renal disease-estimated glomerular filtration rate.

Conclusions: KIR genotyping should be performed at the time of enrolment of patients on the waiting list for organ transplantation. In our study, a significantly higher risk of chronic rejection after kidney transplantation was observed when recipient (r) and donor (d) pairs completely lacked the two functional rKIR-dHLA ligand combinations rKIR2DL1/dHLA-C2 and rKIR3DL1/dHLA-Bw4. This immunogenetic profile corresponds to low levels of NK cell inhibition. Therefore, patients with this high risk profile could benefit from immunosuppressive therapy aimed at reducing NK-cell cytotoxicity.

MeSH terms

  • Adult
  • Cadaver
  • Case-Control Studies
  • Female
  • Gene Expression
  • Glomerular Filtration Rate
  • Graft Rejection / genetics*
  • Graft Rejection / immunology
  • Graft Rejection / pathology
  • Graft Survival / genetics
  • HLA-B Antigens / genetics
  • HLA-B Antigens / immunology*
  • HLA-C Antigens / genetics
  • HLA-C Antigens / immunology*
  • Histocompatibility
  • Humans
  • Kidney Failure, Chronic / immunology
  • Kidney Failure, Chronic / pathology
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation*
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / pathology
  • Ligands
  • Male
  • Middle Aged
  • Receptors, KIR2DL1 / genetics
  • Receptors, KIR2DL1 / immunology*
  • Receptors, KIR3DL1 / genetics
  • Receptors, KIR3DL1 / immunology*
  • Transplantation, Homologous
  • Unrelated Donors

Substances

  • HLA-B Antigens
  • HLA-Bw4 antigen
  • HLA-C Antigens
  • KIR2DL1 protein, human
  • KIR3DL1 protein, human
  • Ligands
  • Receptors, KIR2DL1
  • Receptors, KIR3DL1

Grants and funding

The research performed in this report falls within the institutional responsibilities of the investigators of the participating centers, all of which pertain to the Italian National Public Health Service. The authors received no specific funding for this work. Grant funding (2014-1861) for part of the reagents was received from the “Fondazione Sardegna”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.